Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 105 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Leukemia, Lymphoma
Interventions
ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
New York, New York • Burlington, Vermont
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Ixabepilone + Carboplatin Metastatic Breast Cancer

NCT01075100
Conditions
Metastatic Breast Cancer
Interventions
Ixabepilone, Carboplatin
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
59
States / cities
Phoenix, Arizona • Sedona, Arizona • Tucson, Arizona + 50 more
Conditions
Breast Cancer
Interventions
Eribulin Mesylate, Ixabepilone
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
50
States / cities
Sedona, Arizona • Hawthorne, California • Los Angeles, California + 39 more
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
ixabepilone, bevacizumab
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Breast Cancer
Interventions
CDX-011, "Investigator's Choice" chemotherapy
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 19 more
Conditions
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
ixabepilone, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Ixabepilone, Sunitinib
Drug
Lead sponsor
Jaime Merchan
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Miami, Florida
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
2
States / cities
Detroit, Michigan • New York, New York
Conditions
Advanced Cancer
Interventions
Capecitabine, Doxorubicin, Ixabepilone, Docetaxel, Paclitaxel, Brivanib alaninate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan
Conditions
Breast Cancer, Metastases
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • San Francisco, California • Vallejo, California + 29 more
Completed Phase 1Phase 2 Interventional Results available

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

NCT00182767
Conditions
Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
ixabepilone, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Farmington, Connecticut • Albany, New York • New York, New York + 1 more
Conditions
Carcinoma, Non-small-cell Lung
Interventions
Epothilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
16
States / cities
Birmingham, Alabama • Sacramento, California • Miami Beach, Florida + 12 more
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Taxane, Vinorelbine, Ixabepilone, Eribulin, Chemotherapy
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Head and Neck Cancer
Interventions
cisplatin, ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
hydroxychloroquine, ixabepilone
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Conditions
Cancer
Interventions
Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d, Ixabepilone, 20 mg/d, Ixabepilone, 25 mg/d, Ixabepilone, 30 mg/d, Ixabepilone, 25 mg, with famotidine, Ixabepilone, 25 mg, with food
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Detroit, Michigan
Conditions
Adult Solid Neoplasm
Interventions
Ixabepilone, Pharmacological Study, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Metastatic Breast Cancer
Interventions
LY2523355, ixabepilone, pegfilgrastim, filgrastim
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Fort Myers, Florida • Pensacola, Florida • Gainesville, Georgia + 9 more
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Ixabepilone (Ixempra), Paclitaxel (Taxol)
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
69
States / cities
Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
Conditions
Solid Tumor
Interventions
ixabepilone, Dasatinib
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ixabepilone, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Breast Cancer
Interventions
Sorafenib, Ixabepilone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
15
States / cities
Fort Myers, Florida • Terre Haute, Indiana • Louisville, Kentucky + 10 more
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
trastuzumab, ixabepilone, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts